Diabetes
and its complications are one of the most concerned metabolic
diseases worldwide and threaten human health severely. Hypoglycemic
and hypolipidemic effects of glucomannan extracted from konjac on
high-fat diet and streptozocin-induced type 2 diabetic rats were evaluated
in this study. Administration of konjac glucomannan significantly
decreased the levels of fasting blood glucose, serum insulin, glucagon-like
peptide 1, and glycated serum protein. The concentrations of serum
lipids, including total cholesterol, triacylglycerols, low-density
lipoprotein cholesterol, and non-esterified fatty acid, were notably
reduced by konjac glucomannan treatment. In addition, antioxidant
capacity, pancreatic injury, and adipose cell hypertrophy were ameliorated
by konjac glucomannan administration in type 2 diabetic rats. Besides,
ultra performance liquid chromatography–quadrupole time-of-flight
mass spectrometry-based lipidomics analysis was used to explore the
improvement of lipid metabolic by konjac glucomannan treatment. The
disturbance of glycerolipid (diacylglycerol, monoacylglycerol, and
triacylglycerol), fatty acyl (acylcarnitine and hydroxyl fatty acid),
sphingolipid (ceramide and sphingomyelin), and glycerophospholipid
(phosphatidylcholine) metabolism were attenuated by the glucomannan
treatment. This study provided new insights for investigating the
anti-diabetic effects of konjac glucomannan and suggests that konjac
glucomannan may be a promising nutraceutical for treating type 2 diabetes.